For immediate release |
19 April 2018 |
ANGLE plc ("the Company")
ANGLE'S PARSORTIX SYSTEM SHOWCASED IN MULTIPLE PRESENTATIONS AT LEADING CANCER CONFERENCE AACR 2018
Customers and collaborators publish more successful research with ANGLE's Parsortix circulating tumor cell (CTC) harvesting system in four poster presentations
Well positioned to become the CTC liquid biopsy system of choice
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that its ParsortixTM system was widely showcased by the Company's customers and Key Opinion Leaders in the field of circulating tumour cells (CTCs) in presentations at the American Association for Cancer Research conference (AACR) 2018, in Chicago, 14 to 18 April 2018.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The multiple presentations featuring the Parsortix system at this leading conference for cancer research continues to demonstrate that ANGLE's strategy of promoting the adoption of its CTC harvesting system as the de facto standard for harvesting cancer cells for analysis is working well and generating further utility and evidence of effectiveness. The Parsortix system is compatible with numerous downstream analysis systems and our aim is for it to become the CTC system of choice for cancer liquid biopsy, a growing market that is expected to reach $14 billion in the United States alone by 2025. In pursuit of this objective, following highly successful trials in ovarian cancer, ANGLE has a pivotal clinical study for metastatic breast cancer in progress with the aim of becoming the first company ever to receive FDA clearance for a product to harvest CTCs from blood for subsequent analysis."
ANGLE's Parsortix system was showcased in the following four different poster presentations by leading cancer centres:
Poster Presentations
1) Robert H Lurie Comprehensive Cancer Center and the Feinberg School of Medicine, Northwestern University, Chicago (Northwestern): optimised workflow for the recovery and culturing of CTCs from a simple blood test to produce an effective ex-vivo culture of the patient's cancer cells (see separate announcement released today describing this breakthrough work)
2) Boehringer Ingelheim and University Hamburg-Eppendorf: Detection of CTCs in NSCLC (non-small cell lung cancer) as part of the pan-European Cancer-ID programme which is seeking to standardise protocols for clinical adoption across Europe
3) University of Athens: FISH (fluorescence in situ hybridisation) analysis of CTCs for NSCLC cancer patients to identify HER-2 and c-MET CTCs that may indicate tumor resistance to kinase inhibitor drugs
4) Bayer AG: analysis of DNA mutations in NSCLC using highly sensitive droplet digital PCR as part of the pan-European Cancer-ID programme which is seeking to standardise protocols for clinical adoption across Europe.
When the posters have been publicly released, they will be available on ANGLE's website at https://angleplc.com/library/publications/
For further information ANGLE:
ANGLE plc |
+44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
|
finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne Corporate Broking - Alice Lane, Nikita Jain |
+44 (0)20 7220 0500 |
WG Partners (Joint Broker) Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee |
+44 (0) 203 705 9330 |
FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert Evan Smith, Anne Troy (US) |
+44 (0) 203 727 1000 +1 212 850 5612 |
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the ParsortixTM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix system has a CE Mark for Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of all types is called Ziplex® and is based on a patented flow through array technology. It provides for highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. These technologies can be combined to provide fully automated, sample to answer results in both centralised laboratory and point of use cartridge formats. It is ideal for measuring gene expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/
